Literature DB >> 6403145

Toxic effects of interferon administered intrathecally.

J Ruutiainen, M Panelius, K Cantell.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6403145      PMCID： PMC1547352          DOI： 10.1136/bmj.286.6369.940

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis.

Authors:  J Abb; F Deinhardt; H Zander; R B Tenser; F Rapp; J M Goust; H H Fudenberg; J Vilcek; M Ho; T C Merigan; M B Oldstone; G G Jackson
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

2.  Partial purification of human leukocyte interferon on a large scale.

Authors:  K Cantell; S Hirvonen; V Koistinen
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

3.  Toxicity of interferon.

Authors:  G M Scott; D S Secher; D Flowers; J Bate; K Cantell; D A Tyrrell
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

4.  PPD-, PWM-, and PHA-induced interferon in stable multiple sclerosis: association with HLA-Dw2 antigen and clinical variables.

Authors:  R Salonen; J Ilonen; M Reunanen; J Nikoskelainen; A Salmi
Journal:  Ann Neurol       Date:  1982-03       Impact factor: 10.422

5.  Intrathecal interferon in multiple sclerosis.

Authors:  L Jacobs; J O'Malley; A Freeman; J Murawski; R Ekes
Journal:  Arch Neurol       Date:  1982-10
  5 in total
  1 in total

1.  Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.